GONZALEZ RICHARD A

Director Richard A Gonzalez sold 98,628 shares for $20.3M at blended avg $205.45; post-sale holdings 388.9K shares.

Richard A Gonzalez, a Director of AbbVie, executed 2 separate sales totaling 98,628 shares for $20,263,019.64, reducing his holdings by 20.2% from 487,557 to 388,929 shares. The sales occurred at $205.11 on 2025-02-28 and $210.53 on 2025-03-03, bracketing a modest price move; at the current price of $207.76, the blended average transaction price of $205.45 remains competitively positioned just below the 52-week high of $211.48. His prior 5 sales at ABBV show mixed timing outcomes: 3 of 5 were well-timed at the 90-day mark, though recent sales on 2024-08-05 and 2024-07-17 saw the stock rise 5.6% and 10.8% respectively over 30 days afterward, indicating the insider sold into strength rather than weakness on those occasions. With AbbVie trading at a P/E of 80.84 and the stock up 13.0% over the past 30 days and 17.7% over 90 days, this sale represents a material reduction of a senior insider's position at elevated valuations and following a pronounced uptrend.

Gonzalez sells 66,500 ABBV shares at $186.52; stock up 12.6% in 30d, holdings trim -13.0%.

Gonzalez sold 66,500 shares (66.5K shares) at $186.52 on 2024-08-05 for $12,403,580.00 ($12.4M), reducing holdings by 13.0% vs pre-transaction level. The sale occurred just before ABBV's sharp momentum phase: the stock has gained 12.6% in the prior 30 days and 16.9% in the 90-day period, meaning this trade preceded a substantial rally. His prior three ABBV sales each posted negative 90-day returns (-12.4%, -4.5%, -6.8%), establishing a pattern of well-timed exits before downturns; however, the current price of $187.51 sits -1.2% from the 52-week high of $189.71, and the extended recent gains suggest the timing context differs from his historical pattern. The elevated P/E of 62.09 and annual revenue decline of -6.4% warrant monitoring alongside the significant reduction in his concentrated position.

ABBV Executive Chairman Gonzalez sold 282,845 shares for $49.5M; all 3 prior ABBV sales preceded 90-day declines

Richard A. Gonzalez, Executive Chairman, sold 282,845 shares (282.8K shares) of AbbVie on 2024-07-17 at $175.00, reducing his holdings by 35.5% to 513,099 shares post-transaction. This is a material reduction in position size worth $49,497,875.00. Gonzalez's same-ticker history at ABBV shows a consistent pattern: all 3 prior sales (2024-02-28, 2023-08-01, 2023-07-31) were followed by negative 90-day returns of -12.4%, -4.5%, and -6.8% respectively—a 100% well-timed rate at this ticker. The current price of $172.32 is -5.4% from the 52-week high of $182.10, and the company's annual revenue growth stands at -6.4%, indicating operational headwinds that may have informed the insider's decision to reduce exposure substantially.